Key Players
Competitive Landscape
Competition in fungal protein runs through four business models: scaled yeast producers, dedicated mycoprotein specialists, fungal-fermentation ingredient developers, and precision-fermentation companies at the market boundary. Direct biomass output and host-organism protein production require different downstream equipment and qualification records, which separates capital needs by business model. Direct biomass producers compete on yield and ingredient consistency, and boundary platforms influence food manufacturers through functional performance and industrial fermentation scale.
A March 2025 facility decision marked a shift toward industrial supply capacity for fermentation-derived proteins. Onego Bio selected Jefferson County in Wisconsin for its planned flagship Bioalbumen manufacturing site that month. The Protein Brewery extended its Series B financing in June 2026 to fund larger Fermotein production and commercialization. Large food programs now compare manufacturing readiness with safety status and formulation performance ahead of larger commercial commitments.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In March 2026, Enifer submitted a notified GRAS dossier for PEKILO mycoprotein to the FDA. | Large food manufacturers need regulator-reviewed safety records before long-term sourcing discussions move beyond technical sampling. | Mycoprotein developers are pairing production scale-up with formal regulator-facing dossiers for food applications. | USA food applications offer revenue once FDA review and customer qualification are complete. |
| In June 2026, The EVERY Company announced a fourfold production-capacity expansion with Huvepharma. | Food manufacturers need stable functional proteins when conventional egg supply and pricing become difficult to plan. | Precision-fermentation protein platforms expand industrial output once early commercial orders establish repeat demand. | Bakery and prepared-food programs provide volume routes for fermentation-derived functional proteins at the market boundary. |
| In December 2025, The Protein Brewery received an EIT Food commercialization grant for next-generation Fermotein applications. | Food manufacturers require application evidence before using unfamiliar mycoprotein in health and wellness formulations. | Dedicated mycoprotein companies are funding application validation alongside scale-up and regulatory work. | Health and wellness foods provide additional revenue routes once Fermotein meets customer nutrition and sensory requirements. |
Angel Yeast and Revyve compete in yeast-protein applications, with MycoTechnology and Lallemand Bio-Ingredients covering fungal or yeast-derived food ingredients and Onego Bio influencing specifications at the precision-fermentation boundary.
Source: Future Market Insights, Fungal Protein Market and Mycoprotein Market Reports, 2026-2036.
The reviewed companies cover direct yeast protein, mycoprotein, functional fungal ingredients, and adjacent proteins produced through fungal fermentation hosts.
Who leads the fungal protein market?
Angel Yeast Co., Ltd., The Protein Brewery, Enifer, and Revyve have the clearest current evidence of direct yeast protein or mycoprotein commercialization in the reviewed company set.
Which suppliers have documented qualification or quality approvals?
Onego Bio has an FDA no-questions letter for Bioalbumen produced with a fungal host, and Revyve's Dinteloord facility is FSSC 22000 certified for its yeast-protein production system.
Which companies provide food and beverage fungal-protein products?
Angel Yeast Co., Ltd. supplies yeast protein for food applications, whereas The Protein Brewery and Enifer focus on mycoprotein and Revyve supplies functional yeast proteins.
Which suppliers serve North America and Europe?
Revyve and MycoTechnology maintain commercial activity in North America and Europe through food-ingredient programs and customer application work. Onego Bio and The EVERY Company also operate in North America through fermentation-derived protein programs intended for broader international food use.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Angel Yeast Co., Ltd. | Direct yeast-protein producer with large-scale fermentation and food-application programs. | In January 2026, Starbucks India and SuperYou launched protein cold foam using Angel AngeoPro yeast protein. |
| The Protein Brewery | Dedicated mycoprotein ingredient company commercializing Fermotein in food and nutrition applications. | In December 2025, The Protein Brewery received an EU LIFE grant supporting Fermotein commercialization in dairy-alternative applications. |
| Enifer | Dedicated mycoprotein developer using PEKILO biomass fermentation for food, pet food, and aquafeed. | In May 2026, Enifer and Rovio Pet Foods introduced a dog treat made with PEKILO mycoprotein. |
| Revyve | Functional yeast-protein producer focused on egg replacement and clean-label food formulation. | In September 2025, Revyve announced Series B financing to expand annual production above 1,600 tons. |
| MycoTechnology, Inc. | Fungal-fermentation ingredient developer with protein and taste-modulation programs. | In March 2026, MycoTechnology announced commercial-scale USA availability of Honey Truffle Sweet Protein following self-affirmed GRAS status. |
| Lallemand Bio-Ingredients | Direct yeast-protein producer with broader microbial food-ingredient operations. The Solyve transaction is treated as adjacent fermentation capacity instead of direct protein output. | In July 2025, Lallemand Bio-Ingredients acquired Solyve, an enzyme producer using solid-state fermentation for food applications. |
| Onego Bio | Edge-of-scope precision-fermentation protein producer using Trichoderma reesei as the production host. | In March 2026, Onego Bio and Sigma Foods entered a collaboration covering egg-protein application trials and supply resilience. |
| The EVERY Company | Edge-of-scope precision-fermentation protein producer supplying functional egg proteins from microbial fermentation. | In July 2026, ADM and The EVERY Company announced commercial-scale USA production of OvoPro at ADM's Clinton facility in Iowa. |
Research Methodology
The companies mapped here illustrate the market structure rather than an exhaustive ranking. Inclusion requires current, verifiable evidence that a company supplies fungal protein ingredients, mycoprotein, yeast protein, or directly relevant fermentation services within the defined market scope. Evidence comes from regulatory approvals, third-party certifications, company announcements, product documentation, and public filings. Capabilities are attributed to the stated fungal-protein platform, yeast-protein line, mycoprotein product family, or fermentation service line rather than generalised across broader corporate portfolios. Market-share estimates remain proprietary FMI assessments for the forecast period.
